Search results
13 mar 2018 · Memantine (MEM), an antagonist of extrasynaptic NMDAR, is currently used for the treatment of AD jointly with acetylcholinesterase inhibitors.
- The Latest Advances in the Diagnosis and Treatment of Dementia
Two main types of medication have been approved for the...
- Memantine, Donepezil, or Combination Therapy—What is the best therapy ...
Memantine and donepezil are frequently used in its...
- Dementia treatment versus prevention - PMC
Abstract. Alzheimer disease (AD) and dementia are becoming...
- The efficacy and safety of memantine for the treatment of ... - PubMed
Currently, five pharmacotherapeutic options are available to...
- The Latest Advances in the Diagnosis and Treatment of Dementia
14 gru 2023 · Two main types of medication have been approved for the treatment of dementia including cholinesterase inhibitors and memantine. AD-related dementia can be treated with acetylcholinesterase inhibitors (AChEIs) including donepezil, rivastigmine, and galantamine in various doses based on the severity of the disease.
10 wrz 2020 · Memantine and donepezil are frequently used in its treatment, both as monotherapy and in combination. This multiple treatment comparison meta‐analysis assessed the efficacy of these regimens and placebo in the management of AD.
Memantine (MEM), an antagonist of extrasynaptic NMDAR, is currently used for the treatment of AD jointly with acetylcholinesterase inhibitors. It has been demonstrated that MEM preferentially prevents the excessive continuous extrasynaptic NMDAR disease activation and therefore prevents neuronal cell death induced by excitotoxicity without ...
Abstract. Alzheimer disease (AD) and dementia are becoming increasingly prevalent due to the aging of the global populations. Currently available treatment options, including acetylcholinesterase inhibitors and memantine, only have symptomatic effects and no drugs with disease-modifying properties are available.
Currently, five pharmacotherapeutic options are available to treat Alzheimer's disease: memantine; the three cholinesterase inhibitors donepezil, galantamine, and rivastigmine; and combination treatments with memantine and one cholinesterase inhibitor.
5 lis 2022 · The N-methyl-D-Aspartate receptor antagonist memantine with its less popular monoamine reuptake-inhibiting properties provides beneficial effects in patients with advanced Alzheimer’s disease on an acetylcholine esterase inhibitor treatment regimen.
